The Latest Breaking News from Abbott

CVS and Walgreens are limiting customers to three toddler and infant formulas per purchase as the shortage worsens across the US

Along with much of the globe, US consumers are reeling from a cost of living and supply-chain crisis. One example is a shortage of baby formula caused by a constellation of factors, from rampant inflation to a massive recall over safety concerns.

Parents across the U.S. are scrambling to find baby formula because of supply disruptions and a massive safety recall by manufacturer Abbott

For the first months of her life, Ashley Strom’s daughter seemed uncomfortable much of the time — vomiting frequently, squirming with acid reflux and sleeping poorly.

Why do we have tariffs on imported formula in the middle of a shortage?

Strained supplies are further exacerbated after a recall by manufacturer Abbott, experts say

From Coda to Everything Everywhere All at Once to Abbott Elementary, audiences have been rushing toward optimism but others should criticize at their peril

Since the persistent Ukraine-Russia war, rising inflationary pressures, and Fed's upcoming interest rate hikes are expected to keep the stock market volatile in the near term, investors seek opportunities to invest in large-cap stocks, which hold the potential to generate relatively stable returns. So, we think it could be wise…

Raymond James thinks Abbott Laboratories' (NYSE: ABT) 1Q results were solid and demonstrated the durable nature of ABT's portfolio, as three out of four business segments grew over 10% organically, with Nutrition growing 8% 

Abbott Laboratories (NYSE:ABT) has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50. Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02 billion. Worldwide sales, excluding…

Out-of-stock per centages reached higher than 40 per cent in seven states in first week of April